- Exchange: SIX Swiss Ex
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for Actelion Ltd (ATLN)
| Open: | 57.600 | Day's Range: | 56.850 - 57.950 | Volume: | 570,265 |
|---|---|---|---|---|---|
| Previous Close: | 56.850 | 52wk Range: | 34.145 - 60.000 | 1-Yr Rtn: | +55.62% |
Key Statistics for ATLN
| Current P/E Ratio (ttm) | 18.3387 |
|---|---|
| Estimated P/E(12/2013) | 15.7218 |
| Relative P/E vs. SMI | 0.9020 |
| Earnings Per Share (CHF) (ttm) | 3.1000 |
| Est. EPS (CHF) (12/2013) | 3.6160 |
| Est. PEG Ratio | 1.8699 |
| Market Cap (M CHF) | 7,207.05 |
| Shares Outstanding (M) | 126.77 |
| 30 Day Average Volume | 537,137 |
| Price/Book (mrq) | 3.9758 |
| Price/Sale (ttm) | 3.7553 |
| Dividend Indicated Gross Yield | 1.76% |
| Cash Dividend (CHF) | 1.0000 |
| Last Dividend | 04/22/2013 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/19/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ATLN
Company Profile & Key Executives for ATLN
Actelion Ltd. is a pharmaceutical company that develops and markets synthetic small-molecule drugs against diseases related to the endothelium. The Company's drugs, Veletri and Tracleer, are used in the treatment of heart and pulmonary conditions.
| Jean-Paul ClozelCEO/Co-Founder | Andrew J OakleyExec VP/CFO/Member-Mgmt Bd |
| Otto SchwarzExec VP/COO | Guy BraunsteinExec VP/Head:Clinical Dev |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ATLN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page